US2013243818A1PendingUtilityA1

Composition Comprising Sortase Anchored Surface Proteins of Streptococcus Uberis

Assignee: LEIGH JAMESPriority: Oct 6, 2008Filed: Mar 1, 2013Published: Sep 19, 2013
Est. expiryOct 6, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:James Leigh
A61K 39/092C07K 14/315A61P 31/04A61K 2039/552
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an immunogenic composition comprising one or more Streptococcus uberis proteins, or an immunogenic part thereof, wherein the composition is capable of eliciting an immune response, when administered to a subject.

Claims

exact text as granted — not AI-modified
1 . An immunogenic composition comprising one or more  Streptococcus uberis  proteins selected from the group consisting of SUB1154, SUB1095 and SUB0145, or a protein with 70%, 80%, 90%, 95% or more sequence homology with one or more of SUB1154, SUB 1095 and SUB0145, wherein the composition is capable of eliciting an immune response, when administered to a subject. 
     
     
         2 . The immunogenic composition of  claim 1  comprising one or more  Streptococcus uberis  proteins selected from the group comprising consisting of SUB1154 and SUB1095, or a protein with 70%, 80%, 90%, 95% or more sequence homology with one or more of SUB1154 and SUB 1095. 
     
     
         3 . The immunogenic composition of  claim 1 , wherein the immunogenic composition comprises two or more of the  Streptococcus uberis  proteins SUB1154, SUB1095 and SUB0145, or a protein with 70%, 80%, 90%, 95% or more sequence homology with one or more of SUB1154, SUB1095 and SUB0145. 
     
     
         4 . The immunogenic composition of  claim 3 , wherein the composition comprises the  Streptococcus uberis  proteins SUB1095 and SUB1154, or a protein with 70%, 80%, 90%, 95% or more sequence homology with SUB1095 or SUB1154. 
     
     
         5 . The immunogenic composition of  claim 1 , wherein the immunogenic part of the composition includes at least one epitope from the full-length protein. 
     
     
         6 . The immunogenic composition of  claim 1 , wherein the subject is a mammal, optionally a ruminant. 
     
     
         7 . The immunogenic composition of  claim 1 , wherein the antigenic composition is capable of eliciting an immune response directed to an antigen in the composition, and acts to prevent or reduce infection by  Streptococcus uberis  in a subject to whom the immunogenic composition has been administered. 
     
     
         8 . The immunogenic composition of  claim 1 , wherein the composition comprises a further one or more antigens, in addition to one or more  S. uberis  proteins. 
     
     
         9 . The immunogenic composition of  claim 1 , wherein the composition is used to elicit/produce a protective immune response when administered to a subject. 
     
     
         10 . The immunogenic composition of  claim 1 , wherein the composition is used as a prophylactic or a therapeutic vaccine against  S. uberis.    
     
     
         11 . The immunogenic composition of  claim 1 , wherein the composition further comprises an adjuvant. 
     
     
         12 . The immunogenic composition of  claim 1 , wherein the composition is used as vaccine against infections caused by  S. uberis.    
     
     
         13 . The immunogenic composition of  claim 8 , wherein the vaccine is administered prophylactically to animals at risk of exposure to  S. uberis,  and/or therapeutically to animals who have already been exposed to  S. uberis.    
     
     
         14 . The immunogenic composition of  claim 8 , wherein the composition comprises an immunologically effective amount of antigen comprised of  S. uberis  proteins. 
     
     
         15 . A pharmaceutical composition comprising one or more  S. uberis  proteins selected from the group consisting of SUB1154, SUB1095 and SUB0145, or a protein with 70%, 80%, 90%, 95% or more sequence homology with one or more of SUB1154, SUB1095 and SUB0145, in combination with a pharmaceutically acceptable carrier or excipient. 
     
     
         16 . A method of protecting a human or non-human animal from the effects of infection by  S. uberis  comprising administering to the human or non-human animal a therapeutically effective amount of a composition according to  claim 1 . 
     
     
         17 . A method for raising an immune response in a human or non-human animal comprising administering an immunologically effective amount of a composition according to  claim 1  to the human or non-human animal. 
     
     
         18 . The composition of  claim 1  for use for the prevention and/or treatment of a disease caused by  S. uberis.

Join the waitlist — get patent alerts

Track US2013243818A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.